{
    "clinical_study": {
        "@rank": "43732", 
        "arm_group": [
            {
                "arm_group_label": "Eplerenone", 
                "arm_group_type": "Experimental", 
                "description": "25mg eplerenone given daily for a week, followed by 50mg given for a total of 3 months since commencement of treatment"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to determine the efficacy and safety in treating patients with\n      chronic central serous chorioretinopathy with the drug eplerenone."
        }, 
        "brief_title": "Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy", 
        "condition": "Central Serous Chorioretinopathy", 
        "condition_browse": {
            "mesh_term": "Central Serous Chorioretinopathy"
        }, 
        "detailed_description": {
            "textblock": "-  The goal of the study is to examine the short-term effects and safety of  eplerenone, a\n           systemic anti-aldosterone medication, in a group of patients with central serous\n           chorioretinopathy (CSCR).\n\n        -  There is currently no standard treatment or therapy for chronic CSCR, a potentially\n           debilitating eye disease.\n\n        -  There is evidence that high blood serum corticosteroid levels can cause or worsen CSCR\n\n        -  Eplerenone, a mineralocorticoid receptor antagonist, has been shown to be of visual and\n           anatomic benefit in a small series of 4 patients with chronic CSCR, suggesting that\n           decreasing mineralocorticoid action in the eye may improve signs and symptoms of CSCR\n\n        -  The study's aim is to evaluate a standardized dose of eplerenone in a controlled\n           prospective fashion for chronic CSCR.\n\n        -  The study consists of taking a standard dose of eplerenone, 25mg once daily for a week,\n           followed by 50mg once daily, for a total of 3 months\n\n        -  Patients will be monitored for efficacy and side effects from the beginning of\n           treatment and for 6 months"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic central serous chorioretinopathy (CSCR): Previous diagnosis of CSCR,\n             persistent subretinal fluid on OCT for more than 4 months after initial presentation\n             to the eye clinic\n\n        Exclusion Criteria:\n\n          -  Other retinal disease\n\n          -  Choroidal neovascularization\n\n          -  Diabetes\n\n          -  A history of uveitis\n\n          -  Ocular surgery in the prior 3 months\n\n          -  Allergy to fluorescein or indocyanine green\n\n          -  Pregnancy, lactation or female patients in fertility age not treated with\n             contraceptive pills\n\n          -  Creatinine clearance < 50 ml/min\n\n          -  Hyperkalemia > 5 mmol/l\n\n          -  Patients treated with drugs deactivated by cytochrome P450 3A4 (CYP3A4)\n\n          -  Serum creatinine > 2 mg/dl in men or > 1.8 mg/dl in women\n\n          -  Treatment with potassium sparing agents or potassium\n\n          -  Treatment with Angiotensin converting enzyme (ACE)/angiotensin II receptor blocker\n             (ARB) inhibitors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153125", 
            "org_study_id": "0405-13-TLV"
        }, 
        "intervention": {
            "arm_group_label": "Eplerenone", 
            "intervention_name": "Eplerenone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Eplerenone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tel Aviv", 
                    "country": "Israel", 
                    "zip": "64239"
                }, 
                "name": "Tel Aviv Souraski Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Michaella Goldstein, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Roy Schwartz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael Martinez, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Zohar Wilner, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Shiri Shulman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Oded Ohana, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Shay Keren, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Dafna Goldenberg, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Meira Neuderfer, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chanan Guzner-Gur, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amir Nutman, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Anat Loewenstein, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "michgold@netvision.net.il", 
            "last_name": "Michaella Goldstein, MD", 
            "phone": "97236974361"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Decrease of at least 10% in subretinal fluid thickness as measured by optical coherence tomography (OCT)", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "22684104", 
                "citation": "Zhao M, C\u00e9l\u00e9rier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012 Jul 2;122(7):2672-9. doi: 10.1172/JCI61427. Epub 2012 Jun 11."
            }, 
            {
                "PMID": "20930852", 
                "citation": "Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010 Dec;24(12):1743-56. doi: 10.1038/eye.2010.130. Epub 2010 Oct 8. Review."
            }, 
            {
                "PMID": "18538401", 
                "citation": "Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008 Oct;115(10):1756-65. doi: 10.1016/j.ophtha.2008.04.014. Epub 2008 Jun 5."
            }, 
            {
                "PMID": "19896635", 
                "citation": "Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol. 2010 Feb;149(2):307-315.e2. doi: 10.1016/j.ajo.2009.08.026. Epub 2009 Nov 6."
            }, 
            {
                "PMID": "6682293", 
                "citation": "Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983 Apr;95(4):457-66."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153125"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tel-Aviv Sourasky Medical Center", 
            "investigator_full_name": "Michaella Goldstein", 
            "investigator_title": "Deputy Head Department of Ophthalmology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Tel-Aviv Sourasky Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tel-Aviv Sourasky Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}